Hypereosinophilic cardiomyopathy

Hypereosinophilic cardiomyopathy, more precisely eosinophilic heart disease, includes injury to the myocardium, endocardium, valves and sometimes the pericardium caused by eosinophil infiltration and degranulation.
It does not identify a single etiologic disease: it is the cardiac phenotype of clonal hematologic disorders, vasculitides, drug reactions, parasitic infections, neoplasms, idiopathic hypereosinophilic syndromes and forms limited to the heart.
Presentation ranges from subclinical abnormalities to fulminant eosinophilic myocarditis, intracavitary thrombosis and restrictive endomyocardial fibrosis.

Blood eosinophilia is generally defined by an absolute count above 0.5 × 10⁹/L; values below 1.5 × 10⁹/L are conventionally mild, between 1.5 and 5 × 10⁹/L moderate and above 5 × 10⁹/L severe.
The term hypereosinophilia indicates a persistent count above 1.5 × 10⁹/L, generally documented on at least two separate occasions, or substantial eosinophilic tissue infiltration. Hypereosinophilic syndrome additionally requires organ damage attributable to eosinophils.
The former mandatory six-month waiting period is no longer acceptable when the heart, nervous system or other vital organs are threatened.

The absence of peripheral eosinophilia does not exclude the disease. The count may be normal in early stages, fluctuate, decrease after corticosteroids or remain confined to tissue, as in organ-limited forms.
The magnitude of the count also does not directly measure cardiac severity: a small number of intensely activated and degranulated eosinophils may produce severe injury, whereas high counts may persist without evident myocardial involvement.
Troponin, imaging and, in appropriate cases, biopsy must therefore take precedence over false reassurance provided by a single blood count.

Fibroplastic parietal endocarditis described by Wilhelm Löffler represents the fibrothrombotic phase of eosinophilic heart disease and should not be confused with Davies tropical endomyocardial fibrosis.
The two conditions share apical obliteration, thrombi, subvalvular involvement and restrictive physiology, but in Löffler disease the relationship with eosinophilia is causal and a clonal or reactive source must be sought.
The distinction radically changes treatment because suppression of eosinophil expansion can halt the process before irreversible scarring develops.

Hypereosinophilias are classified as neoplastic or primary, reactive or secondary, idiopathic and, more rarely, familial. This classification is not merely descriptive: it determines molecular testing, urgency, drug choice and prognosis.
In all groups, the heart may be the presenting organ or remain clinically silent, while skin, lung, gastrointestinal tract and nervous system are common concomitant sites.
Attributing heart disease to an idiopathic syndrome is appropriate only after a proportionate and negative etiologic investigation.

In neoplastic forms, a myeloid or lymphoid clone produces eosinophils independently of normal regulatory signals. The entities most responsive to targeted therapy are myeloid or lymphoid neoplasms with tyrosine-kinase gene fusions, including PDGFRA, PDGFRB, FGFR1, JAK2, FLT3 and ETV6-ABL1.
The cryptic FIP1L1-PDGFRA fusion mainly affects men, may be associated with splenomegaly, elevated vitamin B12 and tryptase and marrow fibrosis, and carries a high probability of response to imatinib.
The fusions are not interchangeable: sensitivity, dose and strategy must be defined by the hematologist according to the specific abnormality.

Other clonal causes include chronic eosinophilic leukemia not otherwise specified, acute myeloid leukemia, myelodysplastic or myeloproliferative syndromes, mastocytosis and lymphoid neoplasms. The lymphocytic variant of hypereosinophilic syndrome is instead driven by aberrant T lymphocytes that secrete interleukin 5 and other eosinophilopoietic cytokines.
The T-cell clone may be small and initially not equivalent to lymphoma, but requires surveillance because in some patients it progresses to a lymphoid neoplasm. Flow cytometry and T-cell receptor rearrangement complement morphology and clinical findings.
A high count alone cannot distinguish myeloid production from lymphoid stimulation.

In reactive forms, eosinophils are polyclonal and respond to cytokines produced by allergy, parasites, drugs, immune-mediated diseases, lymphomas or solid tumors. Common asthma and rhinitis often cause mild eosinophilia; very high or persistent values, or values accompanied by organ damage, require a broader explanation.
Helminths with tissue migration, especially Strongyloides, Toxocara, filariae, schistosomes and trichinella according to geography, are relevant. A negative stool examination does not exclude all infections and serology must be selected according to exposure.
Immunosuppression without this preceding assessment may precipitate fatal Strongyloides hyperinfection.

Eosinophilic granulomatosis with polyangiitis combines asthma, eosinophilic disease and necrotizing vasculitis of small or medium vessels. Only a minority of patients are ANCA positive; cardiac involvement is more typical of the ANCA-negative phenotype, dominated by eosinophilic infiltration, and is a major prognostic determinant.
Neuropathy, purpura, sinusitis, pulmonary infiltrates, glomerulonephritis and ischemia due to vasculitis help distinguish it from idiopathic hypereosinophilic syndrome, although boundaries may remain difficult.
Classification criteria must not be used as an automatic substitute for clinical diagnosis.

Hypersensitivity myocarditis is often drug-related and may present with fever, rash, eosinophilia, lymphadenopathy and liver injury, although extracardiac manifestations may be absent. Antibiotics, anticonvulsants, allopurinol, antipsychotics, anti-inflammatory drugs and numerous other molecules have been implicated; there is no closed list.
DRESS syndrome is a severe systemic reaction with a latency often measured in weeks, viral reactivations and possible multiorgan involvement. Myocardial necrosis may progress even after the drug is withdrawn.
A complete chronology of prescriptions, supplements and substances is therefore a diagnostic investigation in itself.

Eosinophils reach the heart through adhesion and chemotactic signals, then release major basic protein, eosinophil cationic protein, eosinophil-derived neurotoxin, peroxidase, leukotrienes, procoagulant factors and cytokines.
These mediators injure endothelium and cardiomyocytes, increase permeability, activate platelets and the coagulation cascade and stimulate fibroblasts. Degranulation may make intact eosinophils difficult to recognize in already damaged tissue.
Immunohistochemistry and expert pathologic assessment improve interpretation.

The classic model distinguishes necrotic-inflammatory, thrombotic and fibrotic phases. In the first, the infiltrate produces edema, transient wall thickening, necrosis and systolic dysfunction; in the second, the injured endocardial surface and hypercoagulable state favor thrombi, especially at the apices; in the third, thrombus organization and repair deposit collagen.
The phases are not obligatory temporal compartments and may coexist in the same biopsy or magnetic resonance study. Early therapy can interrupt progression, whereas late diagnosis may reveal only scar and organized thrombus.
Defining residual activity is more useful than rigidly assigning a stage.

Eosinophilic myocarditis may be focal, diffuse or necrotizing. Edema reduces compliance, mimics hypertrophy and alters conduction and repolarization; diffuse necrosis produces severe dysfunction, arrhythmias and shock.
The right ventricle may be involved together with the left, and pericardial effusion reflects extension of inflammation. In focal forms, ejection fraction and echocardiography may remain normal despite elevated troponin and tissue abnormalities on magnetic resonance.
Normal function therefore does not exclude active disease.

Eosinophilic thrombi also form in regions with preserved contractility, a feature that should raise suspicion when no aneurysm or infarction exists. They may be biventricular, extend from the apices toward the inflow tracts and incorporate the mitral or tricuspid apparatus.
Embolization may affect the brain, coronary arteries, kidneys, spleen, mesentery, retina and limbs or the pulmonary circulation. Eosinophils promote thrombosis through endothelial injury, tissue factor, platelet activation and inhibition of natural anticoagulant systems.
Correction of the eosinophil count complements anticoagulation; it is not an alternative to it.

In the fibrotic phase, apical and inflow-tract endocardium thickens, reduces cavity size and entraps chordae and papillary muscles. The result is mitral or tricuspid regurgitation, atrial dilation, high filling pressures and restrictive physiology.
Ejection fraction may be preserved over a very small volume while cardiac output is reduced. Extensive fibrosis also provides a substrate for arrhythmias and limits reversibility even after complete control of eosinophilia.
This is Löffler cardiomyopathy in the strict sense.

Presentation depends on the cardiac phase and the causative disease. Dyspnea, chest pain, fatigue, palpitations and syncope are common but nonspecific; fever, rash, asthma, neuropathy or gastrointestinal symptoms may precede or accompany cardiac involvement.
Some patients are identified during surveillance of hypereosinophilia, whereas others present with shock or stroke without a previous hematologic diagnosis. Involvement may also be discovered by magnetic resonance in an apparently asymptomatic person.
Surveillance must be proportionate to the cause and should not wait for heart failure.

In the myocarditic phase, pain may mimic pericarditis or acute coronary syndrome, with ST elevation and elevated troponin. Dyspnea results from ventricular dysfunction, edema or pericardial effusion; palpitations and syncope may reflect ventricular tachycardia or advanced block.
The fulminant form progresses over hours or days with hypotension, elevated lactate, oliguria, cold extremities and the need for inotropes or circulatory support. A normal coronary angiogram does not conclude the work-up if the inflammatory picture persists.
Early biopsy may change life-saving therapy.

Necrotizing eosinophilic myocarditis is a particularly aggressive form, with diffuse infiltrate and extensive myocyte necrosis, distinct from the more subtle perivascular infiltration of hypersensitivity myocarditis. It may cause severe biventricular dysfunction and refractory arrhythmias.
The distinction is histologic and has prognostic value, but categories may overlap and a drug reaction may still be severe. Absence of rash or eosinophilia does not eliminate suspicion.
Every recently introduced medication must be reassessed.

The thrombotic phase may remain silent until embolism occurs. Focal neurologic deficit, visual loss, sudden abdominal pain, limb ischemia or infarction with otherwise normal coronary arteries may result from intracavitary material.
Apical thrombi reduce ventricular volume and mimic a mass or hypertrophic cardiomyopathy; when both ventricles are involved, systemic and pulmonary risk coexist. Size does not perfectly predict mobility and embolization.
The search should include all chambers and be repeated during therapy.

In the restrictive phase, exertional dyspnea, orthopnea, edema, hepatomegaly, ascites and early satiety predominate. Mitral regurgitation causes pulmonary congestion; tricuspid regurgitation and right-sided stiffness produce jugular v waves, pulsatile liver and ascites.
Dilated atria favor fibrillation and flutter, whose loss of atrial contribution abruptly worsens filling of stiff ventricles. Low output may present with fatigue, hypotension and renal failure even when ejection fraction is preserved.
The anatomic picture may become irreversible despite normalization of eosinophils.

Hypereosinophilic syndrome frequently involves multiple organs. Pruritus, eczema, urticaria and angioedema point to the skin; cough, dyspnea and migratory infiltrates to the lungs; pain, diarrhea and protein loss to the gastrointestinal tract; paresthesias and asymmetric deficits to peripheral nerves.
Splenomegaly, anemia, thrombocytopenia, constitutional symptoms and elevated vitamin B12 or tryptase suggest a myeloid form. Lymphadenopathy, erythroderma and an aberrant T-cell phenotype point toward the lymphocytic variant or lymphoma.
The extracardiac map selects the most informative biopsy and molecular tests.

In EGPA, adult-onset asthma, chronic rhinosinusitis and nasal polyposis often precede other manifestations. Mononeuritis multiplex, purpura, pulmonary infiltrates, eosinophilia and cardiac manifestations define potentially severe disease even when ANCA are negative.
The ANCA-positive phenotype more frequently shows glomerulonephritis and capillary vasculitis, whereas the ANCA-negative phenotype is more associated with eosinophilic heart disease; the separation is not absolute. Chest pain may also result from coronary vasculitis.
Assessment should include myocardium, pericardium, coronary arteries and valves.

In DRESS, the combination of fever, extensive rash, facial edema, lymphadenopathy, eosinophilia, atypical lymphocytes and liver injury after a new drug should trigger alarm. Myocarditis may appear late, persist after skin improvement and carry high mortality.
Less complete reactions are not harmless and re-exposure to the causative drug may be catastrophic. The drug and molecules with possible cross-reactivity must be documented permanently.
Pharmacovigilance and allergy consultation accompany cardiac care.

Warning signs are chest pain with elevated troponin, syncope, sustained arrhythmia, advanced block, new ventricular dysfunction, apical thrombus, increasing effusion, hypotension or elevated lactate. In a patient with hypereosinophilia they require hospitalization and rapid assessment even if symptoms are mild.
Neurologic deficit, sudden abdominal pain, a cold limb or visual loss suggest embolism. Fever and instability during immunosuppression simultaneously require investigation for infection.
Delaying while waiting for a second eosinophil count may consolidate preventable injury.

The clinical course does not necessarily parallel the count. A spontaneous or treatment-induced fall in eosinophils may occur after toxic granules have already been released into tissue, while troponin and magnetic resonance remain abnormal.
Conversely, asymptomatic hypereosinophilia of uncertain significance requires monitoring but does not prove cardiomyopathy. Response should be measured by symptoms, biomarkers, function, thrombi, tissue activity and control of the cause.
A normal number is not equivalent to anatomic healing.

The diagnostic pathway proceeds in parallel for the heart and the etiology, because treating heart failure without blocking the eosinophil source allows relapse, whereas immunosuppressing without excluding infection or a clone may be dangerous. The first measurement is the absolute count, calculated from the total leukocyte count and eosinophil percentage, not the percentage in isolation.
The complete blood count should be repeated and compared with previous tests; corticosteroids, acute stress and circadian rhythm may alter it. Peripheral smear assesses dysplasia, blasts and other blood-cell lines.
A normal count does not close the work-up when cardiac suspicion is high.

Tests include troponin, BNP or NT-proBNP, creatinine, electrolytes, liver function, LDH, CRP, ESR, albumin, calcium, phosphate and urinalysis. Elevated tryptase and vitamin B12, splenomegaly and hematologic abnormalities support a myeloid form; elevated IgE may accompany reactive forms but is not specific.
ANA, ANCA, complement and other autoantibodies are selected according to phenotype. HIV, parasite serologies and stool testing are guided by exposure, and no universal panel replaces an accurate geographic history.
Normal troponin reduces but does not eliminate the probability of chronic fibrotic disease.

When eosinophilia persists or has clonal features, the hematologist and pathologist determine flow cytometry, bone marrow aspiration and biopsy, karyotyping and molecular biology. Testing for FIP1L1-PDGFRA must use a technique capable of detecting the cryptic deletion; according to the picture, PDGFRB, FGFR1, JAK2, FLT3, ETV6-ABL1, BCR-ABL1, KIT D816V and other targets are studied.
An aberrant T-cell phenotype and T-cell receptor clonality assess the lymphocytic variant. A molecular clone is assigned causal significance only when consistent with hematologic classification.
A negative first panel does not automatically make the case idiopathic.

The electrocardiogram is often abnormal but has no specific sign. ST elevation or depression, T-wave inversion, Q waves, bundle-branch blocks, atrioventricular delays and arrhythmias may mimic ischemia or other myocarditides.
Telemetry and Holter monitoring identify tachycardias, pauses and intermittent blocks; patients with syncope may require longer monitoring. Serial evolution is more informative than an isolated tracing.
A normal ECG does not exclude focal infiltration or a thrombotic phase.

Echocardiography is the first imaging test. In the inflammatory phase it may show walls transiently thickened by edema, global or regional dysfunction, right ventricular impairment and pericardial effusion, but it cannot distinguish the cellular type of myocarditis.
In the thrombotic phase it identifies apical masses, endocardial thickening and cavity reduction; contrast improves definition when the apex is not visualized. Thrombi in still-contractile segments and biventricular masses are particularly suggestive clues in the presence of hypereosinophilia.
In the fibrotic phase, obliteration, dilated atria, restrictive filling and valvular regurgitation appear.

Longitudinal strain may reveal dysfunction before ejection fraction falls, but it is not an autonomous diagnostic criterion. Doppler assesses filling pressures, output and severity of regurgitation; right ventricular function should be described with multiple parameters rather than a single measurement.
Transesophageal echocardiography is useful for atrial thrombi, valves and procedural planning, not for directly characterizing myocardial infiltration. Serial examinations measure the response of thrombus, effusion and function.
Using the same acoustic window and comparing with previous images reduce false variation.

Cardiac magnetic resonance is central in stable patients. T2 and mapping identify edema, cine imaging measures function, early acquisitions distinguish avascular thrombus and late gadolinium enhancement describes necrosis or fibrosis.
A diffuse subendocardial pattern, often apical and not confined to a coronary territory, is suggestive in the eosinophilic context; it may involve papillary muscles and overlap with thrombus. Injury does not obligatorily follow the classic subepicardial pattern of lymphocytic myocarditis.
Magnetic resonance quantifies extent and guides the biopsy site, but cannot identify the cellular type with certainty.

A presentation with pain, ST elevation, troponin elevation and regional abnormalities requires exclusion of acute coronary syndrome by coronary angiography or CT angiography according to stability and probability. Coronary arteries without significant atherothrombosis point toward myocarditis, but embolism from ventricular thrombus, vasculitis, dissection and vasospasm can produce genuine coronary lesions.
CT also defines apices, thrombi, lungs and pericardium when magnetic resonance is contraindicated. FDG PET may show inflammatory activity but does not replace histology and inadequate preparation causes false positives.
Each modality answers a distinct question.

Endomyocardial biopsy is strongly indicated when fulminant or unstable myocarditis is suspected, in severe arrhythmias or blocks and when histologic diagnosis would immediately change immunosuppression. It demonstrates eosinophils, degranulation, necrosis, perivascular or diffuse distribution, thrombus and fibrosis and distinguishes lymphocytic, giant-cell and granulomatous forms.
Multiple sampling, immunohistochemistry and molecular testing for infectious agents improve yield. Focal distribution produces false negatives and, if suspicion remains high, imaging guidance or repeat biopsy may be considered.
The procedure should be performed in expert centers and planned with respect to apical thrombi.

The differential diagnosis includes acute coronary syndrome, lymphocytic or giant-cell myocarditis, sarcoidosis, apical hypertrophic cardiomyopathy, amyloidosis, thrombi from other causes, infective endocarditis, cardiac tumors and tropical endomyocardial fibrosis.
Thickening from edema is not true hypertrophy; nonenhancing thrombus is not myocardium; noncoronary subendocardial late enhancement is not automatically infarction. Tropical fibrosis requires an epidemiologic context and does not by itself demonstrate causal eosinophilia.
Review by cardiologist, hematologist and pathologist avoids inappropriate labels.

A complete diagnosis should name the cardiac phenotype, predominant phase and cause: for example, acute eosinophilic myocarditis with biventricular thrombi in a neoplasm with an FIP1L1-PDGFRA fusion, or fibrotic Löffler endomyocarditis in idiopathic hypereosinophilic syndrome.
Ventricular function, rhythm, valves, embolic events, extracardiac organs and degree of certainty should be added. The isolated term hypereosinophilic cardiomyopathy does not communicate activity or therapeutic target.
The diagnosis is updated as histology and hematologic genetics become available.

Treatment has four simultaneous goals: stabilize the circulation, rapidly suppress eosinophilic injury, treat the cause and prevent thrombosis or fibrotic remodeling. In severe disease, therapy should not wait weeks for classification, but blood, infectious-disease and biopsy samples should be obtained when possible before immunosuppression.
Intensive-care cardiology, hematology, rheumatology, infectious disease, allergy and pathology should coordinate a shared sequence. Normalization of the blood count alone is not a sufficient endpoint.
Troponin, function, thrombi and extracardiac organs guide response.

In eosinophilic myocarditis with significant cardiac injury, systemic corticosteroids are the most commonly used initial therapy; in fulminant forms, intravenous pulses are used followed by oral therapy and individualized tapering. However, no dose and duration regimen has been validated by specific randomized studies.
Tapering too rapidly may promote relapse, whereas prolonged exposure causes infection, diabetes, osteoporosis, myopathy and cardiovascular risk. Addition of a steroid-sparing drug depends on the cause and response.
Empirical immunosuppression of inactive scar offers little benefit.

Before high doses, strongyloidiasis should be assessed on the basis of origin and exposure; if it cannot be excluded in a patient requiring urgent therapy, specialist consensus supports appropriate antiparasitic treatment, often with ivermectin. Other parasitic infections require different drugs and there is no universal prophylaxis.
Samples for cultures, serology and biopsy should not delay life support. Fever while receiving steroids may represent active disease or opportunistic infection and requires reassessment.
Infection prevention accompanies all immunosuppression.

In neoplasms with a sensitive PDGFRA or PDGFRB fusion, imatinib can produce a rapid and profound hematologic and molecular response. Sudden eosinophil lysis in the presence of heart disease could theoretically worsen injury through granule release, which is why corticosteroids and close monitoring are often initially associated in cardiac cases.
Dose, duration, molecular response and the possibility of dose reduction are determined by the hematologist. FGFR1, JAK2, FLT3 or ETV6-ABL1 fusions require different strategies and sometimes hematopoietic transplantation.
Empirical imatinib without a target is not treatment for generic eosinophilia.

In idiopathic hypereosinophilic syndrome, corticosteroids are usually first-line therapy; hydroxyurea, interferon alfa, immunosuppressants or biologic therapies are selected in dependent, relapsing or refractory cases. Anti-interleukin-5 mepolizumab reduced flares in a phase III study of patients with non-FIP1L1-PDGFRA HES and may reduce steroid exposure.
The study was not designed specifically for fulminant myocarditis, so the biologic does not replace corticosteroids and support in the severe acute phase. Benralizumab, reslizumab, alemtuzumab and other targets have more limited evidence or different indications.
Selection requires phenotype, accessibility and monitoring.

In EGPA with severe cardiac involvement, corticosteroids combined with cyclophosphamide are used; rituximab is an alternative in appropriate settings, including to avoid gonadotoxicity in younger patients. Mepolizumab has a role in relapsing or refractory forms that are not immediately life-threatening and as a steroid-sparing agent, but specific data on severe active cardiac disease are limited.
Treatment must cover both vasculitis and eosinophilia and consider the kidneys, nerves, lungs and fertility. Pneumocystis prophylaxis, vaccinations and immune monitoring follow the intensity of the regimen.
ANCA negativity does not mean mild disease.

In hypersensitivity myocarditis or DRESS, the suspected drug must be permanently discontinued and replaced without predictable cross-reactivity. Significant cardiac injury requires corticosteroids and sometimes other immunosuppressants, with treatment lasting longer than skin improvement might suggest.
Identification should not rely on skin testing or provocation during the acute phase. The drug should be recorded in the medical record, communicated to the patient and reported according to pharmacovigilance procedures.
Intentional re-exposure is generally contraindicated after myocarditis.

Heart failure and shock are treated according to hemodynamics with oxygenation, diuretics, vasopressors or inotropes and, if necessary, temporary mechanical support with VA-ECMO or assist devices. Support is a bridge to immunologic response, diagnosis or transplantation, not etiologic therapy.
Beta-blockers, renin-angiotensin system inhibitors, mineralocorticoid antagonists and SGLT2 inhibitors are introduced when compatible with ejection fraction, blood pressure and renal function. In advanced restrictive physiology with fixed output, excessive diuresis and bradycardia are dangerous.
Therapy changes with the phase.

The 2026 ESC consensus recommends anticoagulation in the presence of intracardiac thrombus, atrial fibrillation or flutter and after an embolic event; in the acute phase of eosinophilic myocarditis it may also be reasonable to consider it in many patients without embolism, but randomized studies are lacking. Type and duration depend on location, thrombus resolution, eosinophilic activity, valves, renal function and bleeding.
There are no robust comparisons between vitamin K antagonists and direct anticoagulants in this disease. Serial echocardiography or magnetic resonance documents the response.
Eosinophil control reduces the thrombogenic substrate but does not replace indicated anticoagulation.

Arrhythmias are treated by correcting inflammation, ischemia, electrolytes and heart failure, together with drugs, cardioversion or pacing when necessary. In the potentially reversible acute phase, the decision on a permanent defibrillator may be deferred with selected temporary protection, unless there are overriding indications.
Residual fibrosis and late arrhythmias require new stratification after apparent recovery. Ablation acts on the circuit but not on eosinophilic disease.
Syncope or sustained tachycardia requires urgent specialist assessment.

In stabilized endomyocardial fibrosis, eosinophil suppression prevents further injury but does not remove scar, obliteration or valvular tethering. Endocardiectomy, removal of organized thrombus and mitral or tricuspid repair or replacement may be considered in expert centers when symptoms and hemodynamics remain severe.
Risks include perforation, bleeding, embolism, block, low output and recurrence; the cause must be controlled before and after surgery. Heart transplantation is rare and reserved for noncorrectable end-stage heart failure.
Surgery treats the mechanical consequence, not the clone or vasculitis.

Prognosis varies enormously. Fulminant forms, extensive necrosis, shock, malignant arrhythmias, right ventricular dysfunction, multiple thrombi and late diagnosis worsen outcome; the published case literature probably overestimates mortality because it selects the most dramatic presentations.
An FIP1L1-PDGFRA fusion recognized early can respond extraordinarily well, whereas restrictive fibrosis remains only partially reversible. Relapses depend on control of the cause and quality of maintenance therapy.
Follow-up should continue even after ejection fraction normalizes.

Monitoring includes eosinophil count, troponin, natriuretic peptides, organ function, ECG, echocardiography and assessment of the underlying disease. Magnetic resonance is repeated for activity, scar or thrombus when the result changes therapy; quantitative molecular testing follows clonal forms.
Corticosteroid tapering should be coordinated with cardiac and extracardiac data and not guided by the blood count alone. Education about pain, dyspnea, syncope and embolic signs allows prompt reassessment.
Intense physical activity remains suspended during active myocarditis and is resumed after specialist reevaluation.

The most immediate complication is fulminant myocarditis with biventricular dysfunction, pulmonary edema, shock and multiorgan failure. Blood pressure may collapse before marked ventricular dilation develops because edema and necrosis rapidly reduce contractility and compliance.
Prolonged inotropes may promote arrhythmias and worsen eosinophilia in some settings, while delayed mechanical support allows irreversible injury. Management in a center with biopsy and circulatory-assistance capability improves the chance of targeted therapy.
The critical phase requires close hemodynamic reassessment.

Ventricular arrhythmias and atrioventricular block may cause syncope, cardiac arrest or sudden death. Active inflammation, edema, necrosis, microvascular ischemia and electrolyte abnormalities are acute substrates; scar remains a chronic substrate even after eosinophils are controlled.
Recovery of ejection fraction does not abolish risk if late enhancement, syncope or tachycardias persist. Monitoring and device indications follow the overall profile.
Drugs that prolong the QT interval should be reassessed.

Intracardiac thrombosis and embolism are cardinal complications. Thrombi may form at both apices even with relatively preserved wall motion, grow toward the valvular apparatus and fragment despite regression of the eosinophil count.
Stroke, coronary embolism, mesenteric, renal, splenic, retinal or peripheral ischemia and pulmonary thromboembolism may leave permanent disability or cause death. Anticoagulation in turn exposes patients to bleeding, especially with thrombocytopenia, liver disease or invasive procedures.
Serial imaging and etiologic control balance the two risks.

Endomyocardial fibrosis produces a small cavity, restrictive physiology and mitral or tricuspid regurgitation. Atrial dilation generates fibrillation, stasis and further thrombosis; high left-sided pressure causes pulmonary hypertension and high right-sided pressure causes ascites, congestive hepatopathy and renal failure.
Scar does not respond to steroids like edema and may require surgery or transplantation. Delaying control of inflammation therefore transforms a potentially reversible disease into a permanent mechanical defect.
Prevention of fibrosis is the main objective of early diagnosis.

Pericarditis, effusion and tamponade may accompany myocarditis. An increasing effusion with hypotension requires immediate assessment, but high right-sided pressures may mask classic echocardiographic signs.
Pericardiocentesis relieves compression but not myocardial infiltration, and the fluid contributes to diagnosis only in selected cases. Infection and neoplasia must remain in the differential diagnosis.
Anticoagulation increases the complexity of every pericardial procedure.

Coronary arteries may be involved by embolism, vasospasm, thrombosis or vasculitis, producing true infarction in addition to the pseudo-infarct presentation of myocarditis. Distinction requires coronary imaging and magnetic resonance because antiplatelet, anticoagulant and immunosuppressive therapies are not interchangeable.
In EGPA, coronary vasculitis may coexist with eosinophilic infiltration; in other HES, apical thrombus may embolize. Recurrent pain should not automatically be attributed to the same cause as the first episode.
Anatomy guides treatment.

Extracardiac injury modifies prognosis and treatment safety. Neuropathy may be irreversible, pulmonary infiltrates may impair oxygenation, enteropathy may cause protein loss, renal vasculitis limits drugs and liver injury alters coagulation.
A clonal neoplasm may progress or transform despite cardiac control. The lymphocytic variant requires surveillance of skin and lymph nodes, and parasitic infections may disseminate under steroids.
Follow-up cannot be exclusively cardiologic.

Complications of immunosuppression include opportunistic infections, reactivation of tuberculosis or viruses, Strongyloides hyperinfection, hyperglycemia, osteoporosis, myopathy, infertility and secondary neoplasms. Cyclophosphamide carries gonadotoxic and uro-oncologic risks; rituximab can cause hypogammaglobulinemia and reactivation; anti-eosinophil biologics have specific profiles.
Screening, vaccinations, prophylaxis, fertility preservation and laboratory monitoring should precede or accompany the regimen. Reducing steroids is a goal, but not at the cost of reactivating cardiac disease.
The decision is shared and documented.

Imatinib and other inhibitors can cause cytopenias, edema, hepatotoxicity, interactions and, rarely, cardiovascular effects; rapid destruction of the clone may release eosinophilic mediators. Initial monitoring is particularly close when troponin or imaging is abnormal.
Molecular resistance, poor adherence or uncontrolled discontinuation may cause relapse. Complete hematologic response does not guarantee disappearance of pre-existing cardiac scar.
Cardiology and hematology should interpret symptoms and tests together.

Anticoagulation may cause gastrointestinal, intracranial or procedural bleeding; risk is higher with neoplastic thrombocytopenia, vasculitis, liver failure or drug interactions. The absence of specific comparative evidence requires individualized choice and monitoring.
Stopping too early exposes the patient to recurrent thrombosis if eosinophilia or the endocardial surface remains active; continuing indefinitely without reassessment exposes the patient to avoidable harm. Thrombus resolution is necessary but not always sufficient for discontinuation.
Rhythm, fibrosis and cause contribute to the decision.

Relapse may occur during corticosteroid tapering, discontinuation of a biologic, loss of molecular response or new drug exposure. Sometimes the first evidence is a rise in troponin or a new magnetic-resonance area before symptoms and before an eosinophil-count increase.
A written plan defines which tests to repeat and which thresholds require urgent contact. Re-exposure to the responsible drug should be avoided and communicated to every clinician.
Continuity of care prevents diagnostic delays.

Pregnancy requires planning because volume and heart rate increase cardiac load, while anticoagulants, tyrosine-kinase inhibitors and immunosuppressants have different reproductive risks. Active disease, pulmonary hypertension, severe dysfunction or previous thrombosis increase maternal risk.
Cardio-hematology and obstetric counseling should precede conception when possible; medications should not be stopped autonomously. Somatic clonal abnormalities do not usually imply transmission to the fetus.
Management balances disease control and fetal safety.

Psychological consequences arise from etiologic uncertainty, risk of relapse and prolonged therapies. Fatigue, dyspnea and neuropathy may persist even after tests improve and may limit work and social activity.
Rehabilitation, psychological support and clear information about warning signs reduce avoidance and delayed presentation. In advanced cases, integrated palliative care controls symptoms alongside active therapies.
Quality of life should be measured as a clinical outcome.